Home/Filings/4/0000950170-23-073837
4//SEC Filing

Olinger Margaret 4

Accession 0000950170-23-073837

CIK 0001658551other

Filed

Dec 28, 7:00 PM ET

Accepted

Dec 29, 4:07 PM ET

Size

6.6 KB

Accession

0000950170-23-073837

Insider Transaction Report

Form 4
Period: 2023-12-27
Olinger Margaret
Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2023-12-27$0.37/sh+25,000$9,250276,108 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2023-12-2725,00044,577 total
    Exercise: $0.37Exp: 2029-05-13Common Stock (25,000 underlying)
Footnotes (1)
  • [F1]The shares subject to the option are fully vested and exercisable.

Documents

1 file

Issuer

Amylyx Pharmaceuticals, Inc.

CIK 0001658551

Entity typeother

Related Parties

1
  • filerCIK 0001898725

Filing Metadata

Form type
4
Filed
Dec 28, 7:00 PM ET
Accepted
Dec 29, 4:07 PM ET
Size
6.6 KB